- Home
- MDXG vs CVAC Comparison
MDXG vs CVAC Comparison
Compare MDXG & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXG
- CVAC
- Stock Information
- Founded
- MDXG 2006
- CVAC 2000
- Country
- MDXG United States
- CVAC Germany
- Employees
- MDXG N/A
- CVAC N/A
- Industry
- MDXG Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MDXG Health Care
- CVAC Health Care
- Exchange
- MDXG Nasdaq
- CVAC Nasdaq
- Market Cap
- MDXG 1.1B
- CVAC 1.2B
- IPO Year
- MDXG N/A
- CVAC 2020
- Fundamental
- Price
- MDXG $6.94
- CVAC $5.36
- Analyst Decision
- MDXG Buy
- CVAC Hold
- Analyst Count
- MDXG 1
- CVAC 3
- Target Price
- MDXG $12.00
- CVAC $6.83
- AVG Volume (30 Days)
- MDXG 439.7K
- CVAC 475.8K
- Earning Date
- MDXG 10-29-2025
- CVAC 11-11-2025
- Dividend Yield
- MDXG N/A
- CVAC N/A
- EPS Growth
- MDXG N/A
- CVAC N/A
- EPS
- MDXG 0.21
- CVAC 1.01
- Revenue
- MDXG $363,774,000.00
- CVAC $599,540,810.00
- Revenue This Year
- MDXG $12.68
- CVAC N/A
- Revenue Next Year
- MDXG $8.18
- CVAC $23.95
- P/E Ratio
- MDXG $32.78
- CVAC $5.32
- Revenue Growth
- MDXG 6.85
- CVAC 675.15
- 52 Week Low
- MDXG $5.47
- CVAC $2.37
- 52 Week High
- MDXG $10.14
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- MDXG 46.17
- CVAC 46.28
- Support Level
- MDXG $6.89
- CVAC $5.32
- Resistance Level
- MDXG $7.14
- CVAC $5.41
- Average True Range (ATR)
- MDXG 0.18
- CVAC 0.04
- MACD
- MDXG -0.04
- CVAC -0.00
- Stochastic Oscillator
- MDXG 29.55
- CVAC 44.44
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.